A clinical trial to assess the safety and effectiveness of oral semaglutide (a type 2 diabetes medication) in the treatment of early Alzheimer’s Disease

Occurring Dates
Participant Duration
17 appointments at our Malvern clinic over the course of 3 years. The length of the appointments will vary from 30 min to 3 hours.
State of study

Semaglutide (also known as Ozempic) is a medicine approved for the treatment of type 2 diabetes in Australia.

In this study, the study doctors will investigate if semaglutide has a positive effect on memory function and the ability to carry out daily routines in people with early Alzheimer’s disease. This will be done by comparing semaglutide against placebo on the effect on cognition (memory and other brain functions) and daily functioning.

This study has been approved by the St Vincent's Human Research Ethics Committee (2021/ETH00727)

Participation details

We are seeking participants who meet the following criteria:

  • have early Alzheimer’s disease
  • be between 55 and 80 years old (inclusive).
  • have a study partner (a next of kin or someone you have a close relationship to), who is willing to take part in the study and share information about you
  • if taking an approved Alzheimer's disease treatment, must be on a stable dose of that medication for at least 3 months
  • live in Victoria and can attend a clinic in Malvern

If you are interested in participating or would like more information please contact A/Prof Stephen Macfarlane (details below)

Study Address
Level 1, 322 Glenferrie Road, Malvern VIC 3144
Full Name
A/Prof Stephen Macfarlane
HammondCare Malvern
Phone Number
09 9597 6518